Bluejay Diagnostics, Inc. https://bluejaydx.com A Clinical Stage Diagnostic Company Thu, 05 Jun 2025 04:53:45 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.13 https://bluejaydx.com/wp-content/uploads/2021/10/favicon.png Bluejay Diagnostics, Inc. https://bluejaydx.com 32 32 Bluejay Diagnostics Provides Mid-Year Business and Corporate Update https://bluejaydx.com/2025/06/03/bluejay-diagnostics-provides-mid-year-business-and-corporate-update/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-provides-mid-year-business-and-corporate-update Tue, 03 Jun 2025 17:36:00 +0000 https://bluejaydx.com/?p=4585 ACTON, Mass. , June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update.

The post Bluejay Diagnostics Provides Mid-Year Business and Corporate Update appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass. , June 03, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update.

More details.

The post Bluejay Diagnostics Provides Mid-Year Business and Corporate Update appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting https://bluejaydx.com/2025/04/15/bluejay-announces-abstract-accepted-for-presentation-at-the-2025-society-of-academic-emergency-medicine-saem-annual-meeting/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-announces-abstract-accepted-for-presentation-at-the-2025-society-of-academic-emergency-medicine-saem-annual-meeting Tue, 15 Apr 2025 17:33:00 +0000 https://bluejaydx.com/?p=4583 ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.

The post Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.

More details.

The post Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds https://bluejaydx.com/2025/04/07/bluejay-diagnostics-announces-entry-into-warrant-inducement-transaction-for-approximately-3-7-million-in-gross-proceeds/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-announces-entry-into-warrant-inducement-transaction-for-approximately-3-7-million-in-gross-proceeds Mon, 07 Apr 2025 17:31:00 +0000 https://bluejaydx.com/?p=4580 ACTON, Mass. , April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered.

The post Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass. , April 07, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered.

More details.

The post Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics Announces Reverse Stock Split https://bluejaydx.com/2024/11/13/bluejay-diagnostics-announces-reverse-stock-split/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-announces-reverse-stock-split Wed, 13 Nov 2024 09:10:46 +0000 https://bluejaydx.com/?p=4553 ACTON, Mass. , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board.

The post Bluejay Diagnostics Announces Reverse Stock Split appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass. , Nov. 13, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board.

More details.

The post Bluejay Diagnostics Announces Reverse Stock Split appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering https://bluejaydx.com/2024/06/28/bluejay-diagnostics-announces-closing-of-8-75-million-underwritten-public-offering/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-announces-closing-of-8-75-million-underwritten-public-offering Fri, 28 Jun 2024 09:09:04 +0000 https://bluejaydx.com/?p=4551 ACTON, Mass. , June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm.

The post Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass. , June 28, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm.

More details.

The post Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering appeared first on Bluejay Diagnostics, Inc..

]]> SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients https://bluejaydx.com/2024/06/26/symon-i-study-of-symphony-il-6-suggests-prediction-of-mortality-in-sepsis-patients/?utm_source=rss&utm_medium=rss&utm_campaign=symon-i-study-of-symphony-il-6-suggests-prediction-of-mortality-in-sepsis-patients Wed, 26 Jun 2024 09:07:16 +0000 https://bluejaydx.com/?p=4549 ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock.

The post SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the utility of IL-6 upon initial presentation to the intensive care unit (ICU).

More details.

The post SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America https://bluejaydx.com/2023/02/17/bluejay-diagnostics-signs-collaboration-agreement-with-blood-centers-of-america/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-signs-collaboration-agreement-with-blood-centers-of-america Fri, 17 Feb 2023 15:34:51 +0000 https://bluejaydx.com/?p=4360 ACTON, Mass./WEST WARWICK, R.I., February 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.

The post Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America appeared first on Bluejay Diagnostics, Inc..

]]> ACTON, Mass./WEST WARWICK, R.I., February 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.

More details.

The post Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results https://bluejaydx.com/2022/07/26/bluejay-diagnostics-inc-reports-second-quarter-2022-financial-results/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-diagnostics-inc-reports-second-quarter-2022-financial-results Tue, 26 Jul 2022 14:54:00 +0000 https://bluejaydx.com/?p=4238 Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.

The post Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced financial results for the quarter and six months ended June 30, 2022.

More details.

The post Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test https://bluejaydx.com/2022/07/06/bluejay-completes-planned-clinical-studies-for-symphony-il-6-test/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-completes-planned-clinical-studies-for-symphony-il-6-test Wed, 06 Jul 2022 11:59:00 +0000 https://bluejaydx.com/?p=4214 Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test

The post Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies will be published at the 2022 AACC Annual Scientific Meeting being held July 26th to 28th in Chicago.

More details.

The post Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test https://bluejaydx.com/2022/06/09/bluejay-reports-fda-agrees-to-consider-its-plan-to-pursue-a-de-novo-regulatory-pathway-for-the-symphony-il-6-test/?utm_source=rss&utm_medium=rss&utm_campaign=bluejay-reports-fda-agrees-to-consider-its-plan-to-pursue-a-de-novo-regulatory-pathway-for-the-symphony-il-6-test Thu, 09 Jun 2022 12:40:36 +0000 https://bluejaydx.com/?p=4199 Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test

The post Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test appeared first on Bluejay Diagnostics, Inc..

]]> Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused oBluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test.

More details.

The post Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test appeared first on Bluejay Diagnostics, Inc..

]]>